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ABSTRACT Cryptococcus spp. cause life-threatening fungal infection of the central nervous system (CNS), predominantly in pa-
tients with a compromised immune system.Why Cryptococcus neoformans has this remarkable tropism for the CNS is not clear.
Recent research on cerebral pathogenesis of C. neoformans revealed a predominantly transcellular migration of cryptococci
across the brain endothelium; however, the identities of key fungal virulence factors that function specifically to invade the CNS
remain unresolved. Here we found that a novel, secreted metalloprotease (Mpr1) that we identified in the extracellular proteome
of C. neoformans (CnMpr1) is required for establishing fungal disease in the CNS. Mpr1 belongs to a poorly characterized M36
class of fungalysins that are expressed in only some fungal species. A strain of C. neoformans lacking the gene encoding Mpr1
(mpr1) failed to breach the endothelium in an in vitromodel of the human blood-brain barrier (BBB). A mammalian host in-
fected with thempr1 null strain demonstrated significant improvement in survival due to a reduced brain fungal burden and
lacked the brain pathology commonly associated with cryptococcal disease. The in vivo studies further indicate that Mpr1 is not
required for fungal dissemination andMpr1 likely targets the brain endothelium specifically. Remarkably, the sole expression of
CnMPR1 in Saccharomyces cerevisiae resulted in a robust migration of yeast cells across the brain endothelium, demonstrating
Mpr1’s specific activity in breaching the BBB and suggesting that Mpr1 may function independently of the hyaluronic acid-CD44
pathway. This distinct role for Mpr1 may develop into innovative treatment options and facilitate a brain-specific drug delivery
platform.
IMPORTANCE Cryptococcus neoformans is a medically relevant fungal pathogen causing significant morbidity and mortality, par-
ticularly in immunocompromised individuals. An intriguing feature is its strong neurotropism, and consequently the hallmark
of cryptococcal disease is a brain infection, cryptococcal meningoencephalitis. For C. neoformans to penetrate the central ner-
vous system (CNS), it first breaches the blood-brain barrier via a transcellular pathway; however, the identities of fungal factors
required for this transmigration remain largely unknown. In an effort to identify extracellular fungal proteins that could medi-
ate interactions with the brain endothelium, we undertook a proteomic analysis of the extracellular proteome and identified a
secreted metalloprotease (Mpr1) belonging to theM36 class of fungalysins. Here we found that Mpr1 promotes migration of
C. neoformans across the brain endothelium and into the CNS by facilitating attachment of cryptococci to the endothelium sur-
face, thus underscoring the critical role of M36 proteases in fungal pathogenesis.
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Cryptococcus neoformans is an opportunistic fungal pathogenthat causes life-threatening meningitis, most commonly in
populations with impaired immunity (1). The number of cases of
cryptococcosis worldwide is estimated at 1 million, with more
than 600,000 deaths per year (2). The morbidity and mortality
associated with cryptococcal meningitis are unacceptably high,
especially in HIV-infected populations in resource-poor settings
(3). Without rapid intervention, cryptococcal meningitis is uni-
versally fatal regardless of the immune status of the host (1).
Humans are frequently in contact with C. neoformans through
the inhalation of fungal spores or desiccated cells originating in
environments such as soil and pigeon dwellings (4, 5). In the
healthy population, the host defense can prevent fungal cells in the
lung from causing symptomatic infection (1). However, in pa-
tients with impaired cellular immunity, C. neoformans can estab-
lish pulmonary infection and subsequently spread to other organs
of the body, especially the central nervous system (CNS), where it
causes life-threatening meningitis (1).
The mechanism responsible for C. neoformans’ remarkable
neurotropism has yet to be fully resolved. In order for C. neofor-
mans to invade the CNS, it must first breach the blood-brain bar-
rier (BBB), which serves to protect the organism from circulating
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infectious and toxic agents (6, 7). At the cellular level, the BBB
consists of specialized brain microvascular endothelial cells with
robust tight junctions and few pinocytic vesicles (6). Work by
various groups has provided strong evidence for C. neoformans’
ability to cross the BBB in vitro (8–10) and in vivo (11–14). Three
major pathways have been proposed for the movement of C. neo-
formans across the BBB (15). Paracellular crossing of the BBB
involves the loss of BBB integrity as a result of compromised tight
junctions or injury to the brain endothelium, both of which can
lead to opening of the BBB to facilitate C. neoformans’ entry into
the CNS (9, 11, 13, 16–18). Crossing the BBB via the “Trojan
horse” pathway involves the hijacking of phagocytic cells as a ve-
hicle for C. neoformans to enter the CNS (14, 19, 20). Histological
sections show the presence of cryptococci within macrophage-like
cells either within or outside the capillaries in infected brain sec-
tions (14), suggesting that C. neoformans could have been trans-
ported inside circulating phagocytes. Accumulated evidence to
date, however, suggests that C. neoformans crosses the BBB pri-
marily through the transcellular pathway (8, 10, 15, 21). This
mode of transmigration requires that cryptococci adhere to and
are internalized by the brain endothelium from the luminal sur-
face (blood side). Subsequently, the yeast cells transmigrate
through the endothelial cytoplasm and exit on the abluminal side
(brain side) of the BBB (8, 10, 12). Transcellular crossing has been
observed in many invasive bacterial pathogens (22–25) and in
Candida albicans (26) and has also been suggested for C. neofor-
mans based on in vitro (8–10, 27) and in vivo (8, 12, 21, 28, 29)
studies.
Compelling evidence in the literature supports the involve-
ment of C. neoformans’ cell surface and secreted proteins in CNS
invasion (17, 29–35). For example, the expression of extracellular
phospholipase B (29, 35), urease (11, 12), and laccase (34) con-
tributes to the ability of C. neoformans to cause brain infection. In
addition, a ligand-receptor interaction involving cryptococcal
surface-bound hyaluronic acid (a product of the CPS1 gene) and
the CD44 host receptor has been amply demonstrated to take
place during the adhesion of cryptococci to the brain endothelium
in vitro (36–40). Based on the importance of the extracellular pro-
teome of C. neoformans in CNS infection, we used a proteomic
approach to isolate cryptococcal cell surface proteins and identi-
fied an assortment of proteases and free radical-inducing proteins
with possible roles in CNS invasion (41). One of the candidate
proteins was an uncharacterized fungalysin metalloprotease be-
longing to the M36 peptidase class of proteases that are unique to
some fungi (41). Previous work by Steen et al. (42) also identified
this metalloprotease as being encoded by a gene that is highly
upregulated during CNS infection in a rabbit model of cryptococ-
cal meningitis. C. neoformans metalloprotease is structurally sim-
ilar to a neutral metalloprotease of Aspergillus fumigatus (43, 44)
that is capable of breaking down elastin (45), a protein within
connective tissue that is particularly abundant in lung and arteries.
Accordingly, immunogold localization studies demonstrated that
A. fumigatus secretes a fungalysin metalloprotease into invading
lung tissue (45). The M36 fungalysin class of metalloprotease ap-
pears to mediate some aspects of the host-fungus interaction in
A. fumigatus and some basidiomycetes, but the identities of their
substrates remain unknown (46).
In this study, we identified a novel metalloprotease (Mpr1)
through a screen for mutants of C. neoformans defective in cross-
ing the brain endothelium in an in vitro model of the human BBB.
We found that Mpr1 facilitates the migration of C. neoformans
across the in vitroBBB and the subsequent invasion of cryptococci
into the CNS. Our work indicated that the inability of a strain of
C. neoformans lacking MPR1 (mpr1) to cross the BBB was due to
its failure to adhere to the brain endothelium. As expected, the
mpr1 null strain was significantly less virulent than the wild-type
C. neoformans strain in both the murine inhalation and tail-vein
models of infection due to a significant reduction in brain fungal
burden and brain pathology. This study fills a significant gap in
our understanding of the role of a secreted protease in promoting
the invasion of C. neoformans into the CNS and ultimately in the
development of cryptococcal meningitis. Given the significant
contribution of Mpr1 to C. neoformans’ CNS pathogenesis, this
study may lead the way to the development of novel therapeutic
interventions, and it provides a keen understanding of the funda-
mental mechanism of this important M36 class of fungalysins.
RESULTS
Anewly identifiedmetalloprotease (Mpr1) inC.neoformans.To
determine whether extracellular proteases of C. neoformans pro-
moted fungal disease of the CNS, individual strains of C. neofor-
mans lacking known and predicted proteases were examined in an
in vitro model of the BBB (Fig. 1A) (27, 47). In this model, human
cerebral microvascular endothelial cells (hCMEC/D3 cells) were
grown as a monolayer on a transwell insert submerged in medium
specific for brain endothelial cells such that the luminal and ablu-
minal sides represented the blood and brain sides, respectively.
Cryptococci were added to the luminal side and collected from the
abluminal side approximately 18 h later for CFU determination
(Fig. 1A). Interestingly, a strain ofC. neoformans lacking the newly
identified metalloprotease Mpr1 (mpr1) was defective in cross-
ing the endothelium compared to a wild-type strain of C. neofor-
mans (H99) (Fig. 1B). The inability of the mpr1 null strain to
migrate across brain endothelial cells in the in vitro model of the
BBB was not due to medium effects or an inability to tolerate 5%
CO2 and 37°C, since both H99 and the mpr1 strain behaved
similarly (Fig. 1C; see also Fig. S1A, B, and C in the supplemental
material).
Confocal microscopy demonstrated a surface localization of
Mpr1 in Cryptococcus, indicating that Mpr1 is an extracellular
protein (Fig. 1D). This result was further supported by the pres-
ence of the predicted N-terminal signal peptide in Mpr1 and by
our proteomic analysis, where we identified Mpr1 as a secreted
protease (48). Further in silico analysis of Mpr1 revealed a pre-
dicted prodomain and a peptidase M36 catalytic domain with a
highly conserved Zn2 binding motif (Fig. 1E).
Mpr1mediates attachment of cryptococci to the brain endo-
thelium. The inability of the mpr1 strain to cross the endothe-
lium suggested that Mpr1 promoted transcellular migration by
facilitating an aspect of a multistep process that included adhe-
sion, invasion, transmigration, or extrusion from the brain endo-
thelium (9, 37, 49).
To resolve this further, we examined whether Mpr1 promoted
the attachment of cryptococcal cells to the endothelium using an
assay with the in vitro model of the BBB (8). To collect cells of
C. neoformans that had initially associated with endothelial cells,
Millipore water was added to the top transwell insert, resulting in
the rupture of the endothelial cells (hCMEC/D3). The attached
cryptococcal cells were recovered and plated to determine CFUs.
The CFUs revealed how much of the initial inoculum of the
Vu et al.
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mpr1 strain associated with the endothelium compared to re-
sults for H99 and the reconstituted strain (mpr1::MPR1).
We found that Mpr1 was required for associating cryptococci
with brain endothelial cells. This was demonstrated by the low
CFU counts for the mpr1 strain compared to those for H99 and
the reconstituted strains (mpr1::MPR1) following either a 20-
min (Fig. 2A) or 2-h coincubation (Fig. 2B) between cryptococci
and the endothelium. Increasing the incubation time of the
mpr1 strain with the brain endothelium to 8 h did not enhance
its attachment (Fig. 2A). After a 24-h coincubation, significantly
fewer mpr1 cryptococci crossed the endothelium, in stark con-
trast to results for H99 and the reconstituted strains, suggesting
that cryptococci could not migrate across brain endothelial cells in
the absence of Mpr1 (Fig. 2C).
Taken together, the results suggested that Mpr1 was likely re-
quired for attaching cryptococci to the surface of the brain endo-
thelium; however, we could not rule out the possibility that Mpr1
might instead be required for survival within brain endothelial
cells given that the cell association assay could not distinguish
between adherence-defective cryptococci and those that might be
inviable in endothelial cells. To address this issue, we performed
intracellular survival assays using a macrophage-like cell line
FIG 1 A novel metalloprotease (Mpr1) is required for the migration of Cryptococcus neoformans across the brain endothelium. (A) A schematic representation
of the in vitro model of the BBB. A monolayer of hCMEC/D3 cells grown on transwell inserts submerged in medium such that the luminal and abluminal sides
represented the blood and brain sides, respectively. Cryptococci were added to the luminal side and collected from the abluminal side approximately 18 h later
for CFU determination. (B) Strains ofC. neoformans lacking the genes encoding various proteases (H99 serotype A background; see Materials and Methods) were
tested for their ability to transmigrate the brain endothelium in the in vitro model of the BBB. The strain D (mpr1 null strain, H99 serotype A background) was
defective in crossing the endothelial barrier (*, P 0.009) (n 9). (C) CFUs representing cryptococci of the wild-type (H99) and mpr1 strains, equally able to
proliferate in hCMEC/D3 growth medium and conditions in the absence of endothelial cells (n  9). (D) Mpr1 is an extracellular protein. An MPR1-dsRED
fusion protein was expressed in thempr1 background strain to assess its localization. Confocal microscopy of an MPR1-dsRED fusion protein under the control
of an ACTIN promoter revealed a surface localization (scale bar 10m). (E) A schematic diagram of the predicted structure of Mpr1 illustrates the N-terminal
signal sequence, the predicted prodomain (FTP region, Pfam), and the peptidase M36 domain with the conserved Zn2-binding site.
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(J774A.1). The J774A.1 lung macrophages were challenged with
either H99 or the mpr1 null strain of C. neoformans. The mpr1
null strain did not display any significant difference in its ability to
survive within macrophages compared to the H99 strain, indicat-
ing that Mpr1 is not required for intracellular survival (Fig. 2D
and E). Thus, these data further support the notion that Mpr1
mediates the attachment of cryptococci to the brain endothelium.
S. cerevisiae gains the ability to migrate across the brain en-
dothelium upon the sole expression of CnMpr1. Given that Sac-
charomyces cerevisiae does not express metalloproteases from the
M36 fungalysin class, we sought to examine whether the expres-
sion of C. neoformans MPR1 (CnMPR1) in S. cerevisiae might
generate a transformed strain capable of attaching to and pene-
trating the brain endothelium. A positive outcome with this ap-
proach would provide further support for the role of Mpr1 in
transmigration.
In order to test this, we subcloned the cDNA of CnMPR1 ad-
jacent to the GPD promoter of an episomal 2 plasmid and ex-
pressed it in a wild-type strain of S. cerevisiae. Reverse transcrip-
tase PCR confirmed expression of the CnMPR1 transcript in S.
cerevisiae (Fig. 3A). The MPR1 transcript was not detected in S.
cerevisiae alone or in the mpr1 null strain, as expected. To exam-
ine whether Mpr1 retained proteolytic activity when expressed in
S. cerevisiae, the recombinant His-tagged Mpr1 protein was iso-
lated from S. cerevisiae and purified by nickel affinity chromatog-
raphy. Mpr1 activity was measured by using a soluble fluorescein
isothiocyanate (FITC)-labeled casein enzymatic assay (50). The
assay revealed that the Mpr1 recombinant protein maintained
FIG 2 Mpr1 promotes the adherence of Cryptococcus neoformans to brain endothelial cells. Shown are CFUs representing the number of cryptococci adhering
to brain endothelial cells following 20 min or 8 h of coincubation (A) or a 2-h incubation (B) of H99 or the MPR1 (mpr1::MPR1; reconstituted strain) and
mpr1mutant strains with the endothelium in the in vitro model of the BBB. The mpr1mutant strain did not adhere to brain endothelial cells (***, P 0.002)
(n 9). (C) The CFUs representing cryptococci that transmigrated to the abluminal (brain) side of the endothelium following a prolonged incubation with the
brain endothelium revealed that thempr1mutant strain did not transmigrate. (D and E) Wild-type (H99) andmpr1 cells were incubated with the macrophage
cell line J774A.1 to analyze intracellular survival. Following a 1-h coincubation at 37°C in 5% CO2, extracellular cryptococci were removed and the cocultures
were either lysed and plated for CFU analysis (D) or replenished with fresh medium and incubated for an additional 23 h (overnight) at 37°C in 5% CO2 to
determine intracellular viability of cryptococci (E). Following either a 1-h or overnight coincubation, cryptococci were collected from macrophages, plated on
YPD medium, and incubated at 30°C for 2 days for CFU determination. The two strains were similar in their ability to survive within macrophages (n  9).
Statistical significance was determined by an unpaired t test with Welch’s correction (GraphPad Prism5 software).
Vu et al.
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proteolytic activity comparable to that of the trypsin control
(Fig. 3B). Remarkably, the sole expression of CnMpr1 protein in
S. cerevisiae resulted in the attachment (Fig. 3C) and migration of
yeast cells across brain endothelial cells in the in vitro model of the
BBB, strongly supporting a primary role for Mpr1 in attaching and
penetrating the brain endothelium (Fig. 3D).
Extracellular changes at cryptococcus-brain endothelium
interface in absence of Mpr1. We questioned whether Mpr1
might directly impact the fungus-brain endothelium extracellular
environment such that the lack of MPR1 might result in specific
physical changes to this interface. Scanning electron microscopy
(SEM) was used to examine the surface structure of both crypto-
cocci and brain endothelial cells. SEM micrographs revealed sur-
face changes both to cryptococci lacking Mpr1 and to the brain
endothelium (Fig. 4). Upon examination of C. neoformans in the
absence of brain endothelial cells, the mpr1 null strain appeared
to have a more porous surface than that of H99 cells (Fig. 4A and
B). This was not due to a lack of capsule production, since both
mpr1 and H99 strains displayed India ink-stained capsule (data
not shown). Upon coincubation of H99 with brain endothelial
cells, microvillus-like structures were observed on the surface of
the endothelium (indicated by arrows in the figure); however, the
endothelium alone did not produce these structures, thus sup-
porting the notion that these protrusions likely promote transmi-
gration of cryptococci, as previously reported (Fig. 4C, E, and G)
(8, 26, 27). Interestingly in the presence of mpr1 strain, the
microvillus-like structures appeared less abundant (Fig. 4D and
F). Taken together, the data suggest that Mpr1 activity appears to
alter the extracellular landscape of the fungus-brain endothelium
interface (23, 24).
Mpr1 promotes pathogenesis of C. neoformans in the inha-
lation murine model. We next determined the contribution of
FIG 3 Expression of CnMPR1 cDNA in Saccharomyces cerevisiae (Sc) resulted in the attachment to and migration of S. cerevisiae across the brain endothelium.
(A) Reverse transcriptase PCR confirmed the expression of the CnMPR1 transcript in S. cerevisiae. The band corresponding to the MPR1 transcript is absent in
thempr1 and S. cerevisiae (wild-type) strains, as expected. Actin is shown as an internal control for H99 given the typical faint appearance of theMPR1 transcript
in H99. cDNA of CnMPR1was subcloned adjacent to a GDP promoter in a yeast episomal 2 expression vector. (B) A recombinant CnMpr1-His-tagged protein
isolated via nickel chromatography from a yeast S. cerevisiae strain transformed with CnMPR1-HIS cDNA (ScCnMPR1-HIS) retained proteolytic activity (n
 3). Trypsin activity is shown as a positive control for the proteolytic assay. (C) A 4-h coincubation of the ScCnMPR1 strain with brain endothelial cells in
the in vitro BBB model resulted in a significant increase in the ability of yeast cells to associate with the surface of endothelial cells following a 4-h coincubation
(*, P 0.0294; n 9). (D) The ScCnMPR1 strain migrated across the brain endothelial cells following an overnight coincubation. Transformed yeast cells
(ScCnMPR1) were added to the luminal side of the in vitro model of the BBB and collected from the abluminal side for CFU determination (*, P 0.009; n
 9). Shown areC. neoformans strains (CnWT and Cnmpr1) and S. cerevisiae strains (ScWT and ScCnMPR1: yeast strain transformed with cDNA ofMPR1
from C. neoformans).
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Mpr1 to the virulence of C. neoformans in terms of survival and
CNS invasion after pulmonary infection in a mammalian host.
Mice were inoculated via the intranasal route to mimic the natural
path of infection. By day 37 postinfection (p.i.), no mortality had
occurred in mpr1 strain-infected mice, whereas 85% of H99-
infected mice died (Fig. 5A) (P 0.001), and at day 52 p.i., 15% of
mpr1 strain-infected mice remained alive. These results demon-
strated that the lack of Mpr1 significantly prolonged survival, in-
dicating its major role in the pathogenesis of C. neoformans.
Total-lung CFU analysis at the time of death (Fig. 5A) and
10 days p.i. (Fig. 5D) revealed a high cryptococcal burden in
mpr1 strain-infected mice, similar to CFU in lungs of mice in-
fected with H99 (Fig. 5D). These data indicated that improved
survival of mpr1 strain-infected mice was not due to enhanced
clearance of the mpr1 strain-induced infection from the lungs,
the primary site of infection. However, lack of MPR1 from C. neo-
formans significantly reduced the fungal burden in the brain fol-
lowing pulmonary inoculation (Fig. 5C) (P  0.009, CFU mea-
sured at time of death), suggesting a crucial role for Mpr1 in the
transmigration ofC. neoformans into the CNS. Examination of the
fungal burden in the heart, spleen, and kidney following pulmo-
nary infection further demonstrated that the mpr1 strain colo-
nized other organs similarly to colonization by H99, suggesting
that cryptococci do not require Mpr1 to exit the lung nor to invade
other vascular endothelia (Fig. 5D) (P 0.05 for all tissues).
Mpr1 promotesmigration ofC. neoformans across the brain
endothelium. When mice were inoculated via a more direct route
to the brain (tail vein injection), we found that by day 21 p.i.,
100% of mpr1 strain-infected mice were alive and 100% of H99-
infected mice had died, suggesting that the lack of MPR1 in the
pathogen significantly prolonged survival of the host (Fig. 6A) (P
 0.0002). Upon examination of fungal burden at 48 h p.i. in
whole brains of mice infected with the mpr1 strain and H99,
numbers of CFU revealed a significant increase in cryptococci in
whole brains of mice infected with H99 but dramatically less fun-
gal burden in the brains from mpr1 strain-infected mice
(Fig. 6B) (P 0.0001). By 16 days p.i., the brain fungal burden in
mice inoculated with the mpr1 strain remained significantly
lower (Fig. 6C). Given that our histological analysis (Fig. 7) re-
vealed no pathology in brains of mice infected with thempr1null
strain, it is very likely that the CFU observed at 12 h postinfection
are a reflection of cryptococci that have been trapped within small
microvessels because they are unable to adhere to and cross the
blood-brain barrier. This is reminiscent of findings of a previous
study that showed that prior to actively transmigrating through
the brain endothelium, C. neoformans can become mechanically
trapped in small brain capillaries independent of rolling and teth-
ering along the surface of the endothelium (12).
Taken together, the in vivo data strongly suggested that the
mpr1 fungal strain was defective in crossing the brain endothe-
lium and invading the brain parenchyma. However, we could not
rule out the possibility that the significantly lower CFU counts
detected in whole brains of mice infected with the mpr1 strain
might instead reflect a requirement for Mpr1 in intraparenchyma
brain survival. To address this, mice were directly inoculated with
cryptococci (H99 or the mpr1 strain) by intracranial injections
into the brain, and survival of the strains within the brain paren-
chyma was assessed by determining CFU counts for isolated
brains (51). The results show that the mpr1 strain and H99 were
equally able to proliferate within the brain (Fig. 6D). Thus, we
concluded that Mpr1 is not required for the growth and survival of
C. neoformanswithin the brain; instead, Mpr1 functions primarily
to attach cryptococci to the surface of the brain endothelium.
Mpr1 contributes to brain pathology in amurinemodel. We
determined the extent of brain pathology in mpr1 strain-
infected mice by histochemical analysis of mice inoculated via the
tail vein by examining at least 12 brain slices from mice infected
with either H99 or the mpr1 strain after 12 h, 24 h, and 48 h p.i.
Cryptococcal filled lesions were consistently observed in the brain
parenchyma of H99-infected mice 48 h p.i., often in close prox-
imity to microvessels. In a representative image shown in Fig. 7A,
cryptococci at various stages of division were easily identified
within cysts that occurred throughout the brain tissue. Similarly,
FIG 4 Mpr1 alters the extracellular environment of the fungus-endothelium
interface. Scanning electron micrographs of cryptococcal cells from H99 and
mpr1 strains reveal physical differences at the brain endothelium-fungus
interface. In the absence (A and B) or presence (C to F) of hCMED/D3 cells
(brain endothelial cells), the mpr1 null cells displayed a more porous surface
than H99 cells (indicated by arrows). (C and E) Exposure of hCMED/D3 cells
to H99 revealed extensive microvillus-like structures that appeared to be less
abundant upon coincubation with mpr1 cells (D and F) (indicated by ar-
rows). The microvillus-like protrusions were not observed on the surface of
hCMED/D3 in the absence of C. neoformans (G) (scale bar  2 m unless
noted differently in the figure).
Vu et al.
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cryptococci were also observed within lesions in brains from mice
at 12 h and 24 h p.i. (Fig. 7E and G). In stark contrast,
cryptococcus-filled cysts were not detected in brains from mice
inoculated with thempr1 strain at 12 h, 24 h, or 48 h p.i. Remark-
ably here we observed intact brain tissue with healthy microvessels
that were devoid of cryptococci (Fig. 7B, D, F, and H).
DISCUSSION
Although it has been known that C. neoformans expresses several
different types of proteases, this is the first clear demonstration of
a specific role for a secreted protease in CNS invasion. We first
identified the metalloprotease (Mpr1) in a proteomic study aimed
at isolating and identifying extracellular proteins of C. neoformans
(41). Among the extracellular proteome, we found that Mpr1 be-
longed to a relatively uncharacterized, new class of secreted fun-
galysins (the peptidase M36 family) whose substrates have yet to
be fully characterized (41, 46). This class of metalloproteases is
most closely related to the bacterial thermolysin family, whose
members have been implicated as key factors in the pathogenesis
of many diseases (46). The fungal M36 class was first described for
Aspergillus fumigatus, where the metalloprotease MEP42 was
shown to target elastin in human lungs (45, 52). Mounting evi-
dence further supports the notion that fungalysins promote dis-
ease by targeting factors in both mammalian and plant hosts, and
they have also been implicated in fungal disease in amphibians
and insects, but the substrates in most cases have not been re-
solved (52–55).
Genome sequence analysis has revealed that not all fungi ex-
press fungalysins; for example Saccharomyces cerevisiae and Neu-
rospora crassa have none, while Coprinopsis cinerea has eight pre-
dicted fungalysins (46). In the case of C. neoformans, only one
fungalysin is present in its genome (46). Here we demonstrated
that this fungalysin, which we refer to as Mpr1, facilitates the mi-
gration of C. neoformans across the brain endothelium and the
subsequent invasion into the CNS. Our study proposes that the
inability of the mpr1 null strain to cross the brain endothelium
was due to its failure to adhere to the brain endothelium, and as
expected, mice infected with the mpr1 null strain showed signif-
icant improvement in survival due to a reduced brain fungal bur-
den, and the brain pathology that is commonly seen in cryptococ-
cal meningoencephalitis disease was absent.
The inability of the mpr1 strain to migrate across the brain
endothelium suggests that Mpr1 promotes the transcellular cross-
ing of cryptococci by facilitating an aspect of a complex series of
events that include attachment to the endothelium luminal sur-
face, internalization, transmigration and extrusion from the ablu-
minal side of the brain endothelium (9, 37, 49). Despite the limi-
tations of the attachment assay performed here with the in vitro
FIG 5 The murine inhalation model inoculated with a strain of Cryptococcus neoformans lacking Mpr1 showed significant improvement in survival due to a lack
of fungal burden in the brain. (A) Shown is percent survival of mice inoculated via the nares, mimicking the natural route of infection, with the H99 (wild type),
mpr1, andMPR1 (mpr1::MPR1; reconstituted strain) strains.Mpr1 strain-infected mice showed a significant improvement in survival (P 0.001, Wilcoxon
test, sample size determined by power analysis [GPower3.1]) (B and C) CFUs representing the fungal burden at the time of death in lungs (B) or brains (C) of
mice inoculated with H99, thempr1mutant, and theMPR1-reconstituted strains revealed significantly less fungal burden in brains from mice infected with the
mpr1 mutant strain (**, P  0.009). (D) Following 10 days p.i. (postinfection), mpr1 strain-infected mice and H99-infected mice showed similar fungal
burdens in lungs, kidneys, spleen, and heart, suggesting that Mpr1 is not required for dissemination out of the lung and Mpr1 does not play a role in breaching
other vascular endothelia (P 0.05 for all tissues).
Fungal Metalloprotease Promotes Invasion of CNS
May/June 2014 Volume 5 Issue 3 e01101-14 ® mbio.asm.org 7
model of the brain endothelium, three separate observations
strongly suggest that Mpr1 promotes the attachment of crypto-
cocci to the endothelium and does not play a role in the intracel-
lular survival of cryptococci. First, significantly fewer cells of the
mpr1 strain associated with the brain endothelium following
only a 20-min coincubation, before most cryptococci had been
internalized. Second, Mpr1 was not required for the intracellular
survival of cryptococci, as demonstrated by the assays performed
with the macrophage cell line. Given that the mpr1 strain can
survive as well as H99 in a professional phagocytic cell like an
activated macrophage, it would seem probable that mpr1 cells
likely survive within brain endothelial cells. Third, the sole expres-
sion of CnMPR1 in S. cerevisiae resulted in a significant migration
of the transformed yeast strain across the brain endothelium,
demonstrating that the strain likely attached to the endothelial
surface prior to crossing. Last, direct intracranial inoculations in
the murine model revealed that the mpr1 strain was as viable as
H99 within the brain parenchyma, and although this may not
reflect survival within host cells, it does indicate that survival
within a harsh and restrictive environment like the brain is inde-
pendent of Mpr1. Taken together, these results strongly support
the notion that Mpr1 mediates that attachment and/or association
of C. neoformans with the surface of the brain endothelium.
In C. neoformans, surface-bound hyaluronic acid serves as a
ligand for the CD44 host receptor and mediates adherence of
cryptococci to the brain endothelium in vitro (36–40). Interest-
ingly, it has been shown that S. cerevisiae does not naturally ex-
press hyaluronic acid but can be engineered to do so upon expres-
sion of a hyaluronic acid synthase gene (CPS1). We found that the
sole expression of CnMPR1 in a wild-type strain of S. cerevisiae
resulted in a robust migration of yeast cells across the brain endo-
thelium, but given the lack of hyaluronic acid in yeast, the
CnMPR1-transformed S. cerevisiae strain is likely crossing the
brain endothelium independently of the CD44 pathway. Given
this observation, CnMpr1 likely targets other host components
that may alter endothelium permeability and thus facilitate cryp-
tococcus migration into the CNS.
Consistent with these observations and previous reports, the
movement of C. neoformans across the brain endothelium ob-
served in the in vitro BBB model was indicative of a transcellular
mechanism whereby cryptococci crossed the endothelium with
little or no disruption of the intercellular tight junctions; thus,
protein complexes that constitute the tight junctions of the brain
endothelial cells are likely not substrates of Mpr1 activity. This
observation is further supported by previous reports demonstrat-
ing that cryptococci breach the endothelium through an active
process via a receptor-mediated event involving the formation of
microvillus-like structures on the surface of endothelial cells that
likely facilitate the transcellular movement (8, 11, 12, 14, 27). We
found that Mpr1 appears to alter the physical characteristics of the
FIG 6 Association of cryptococci with the brain endothelium requires Mpr1 in the tail-vein murine model. (A) The percent survival of mice inoculated via a
more direct route to the brain (tail vein) with the H99 and mpr1 strains revealed a dramatic improvement in survival of mice infected with the mpr1 strain.
(B and C) CFUs representing the fungal burden in brains of mice following 12 h, 24 h, and 48 h (B) or 16 days (C) postinfection with the H99 and mpr1 strains
revealed significantly less fungal burden in brains of mice infected by the mpr1 null strain. (D) The number of cryptococci that survived within brain
parenchyma of mice following inoculation by direct intracranial injection of the wild-type and mpr1 strains revealed no significant differences between strains.
(Asterisks correspond to P values. **, P 0.008; ***, P 0.001.)
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extracellular environment of the cryptococcus-endothelium in-
terface as noted in the SEM micrographs, but how these structural
changes relate to the targets of Mpr1 activity remains to be seen.
The in vivo studies clearly demonstrate that Mpr1 plays a sig-
nificant role in the virulence of C. neoformans, and several obser-
vations suggest that its role is specific to the pathogenesis of the
CNS. First, the significant reduction in the fungal burden in the
brain of mice infected with the mpr1 strain, the ability of the
mpr1 null strain to survive within brain parenchyma, and the
lack of brain pathology all suggest that Mpr1 is required for at-
taching cryptococci to the surface of the brain endothelium in
vivo, consistent with the in vitro data. Second, the ability of the
mpr1 strain to disseminate out of the lungs and into other vas-
cular beds point to a role for Mpr1 that could be specific for the
brain endothelium. Interestingly, brain sections were devoid of
immune cells, as demonstrated by the lack of neutrophils in brain
sections stained with hematoxylin and eosin (H&E). The lack of
immune cells in the histochemical analysis of brain tissue is con-
sistent with findings of previous work that demonstrated that both
in humans and in mice, inflammation in the brain tissue was lim-
ited, presumably due to late production of low concentrations of
tumor necrosis factor (TNF) alpha and interleukin-6 in brains of
infected mice (14, 56, 57). In addition, only low concentrations of
these cytokines were found in the cerebrospinal fluid (CSF) of
patients with AIDS who suffered from cryptococcal meningitis
(14, 56, 57).
This study further supports the notion that multiple virulence
factors in addition to Mpr1 likely come into play during invasion
of the CNS. In our murine studies, at the time of death, some
cryptococcal cells could be detected in brains from mpr1 strain-
infected mice, indicating that other virulence factors (and other
mechanisms, such as “Trojan horse”: phagocyte-associated inva-
sion) may be involved in promoting CNS fungal disease (11, 20).
For example, urease has been shown to promote the sequestration
of cryptococcal cells within the brain microvasculature (11). In-
creasing evidence about cryptococcal virulence factors in CNS dis-
ease would suggest that a combination of factors, rather than a
single one, is most likely involved in the complex, multistep pro-
cess of cryptococcal dissemination and CNS invasion. In addition,
prolonged exposure of the brain endothelium to cryptococci re-
sults in disruption of brain endothelial cells and the eventual
breakdown of the barrier, thus allowing the passive movement of
cryptococci into the brain (12, 14, 16, 58, 59).
In conclusion, we propose a targeted role for Mpr1 in estab-
lishing fungal disease of the CNS by promoting the attachment of
C. neoformans to the blood-brain barrier. Since Mpr1 represents a
major tactic used by cryptococci to invade the CNS, blocking its
function may promote development of a novel therapeutic inter-
vention, and coupling it to nanocarriers may give rise to a brain-
specific drug delivery system.
MATERIALS AND METHODS
Transcytosis screen for mutants defective at crossing the in vitro BBB
model. The in vitro model of the BBB was established here as previously
described (27). Briefly, the in vitro BBB model consists of a transwell
apparatus separating the luminal (blood) and abluminal (brain) side of
the BBB. hCMEC/D3 cells were grown in the top transwell chamber on a
collagen-coated microporous membrane (8 m). Fungal cells (1  105
cells) were added to the top chamber and collected subsequently from the
bottom chamber for CFU determination. The Cryptococcus neoformans
null strains used in the transcytosis assays shown in Fig. 1 are as follows:
wild type, H99; A, putative disintegrin; B, putative protease; C, putative
secreted hydrolase; D, Mpr1; E, serine protease; F, IgA1 protease; G, pro-
pyl endopeptidase. The strains lacking each gene were obtained from a
library of ~1,200 deletion strains of Cryptococcus neoformans (MAT,
serotype A, var. grubii) (ATCC CNKO-PS).
FIG 7 Brains from mice inoculated via the tail vein with the strain lacking
Mpr1 revealed a complete lack of brain pathology, suggesting that Mpr1 is
required for fungal invasion of the CNS. Mice were inoculated by tail-vein
injection, and brains were examined at 12 h, 24 h, and 48 h p.i. by taking 20
consecutive, longitudinal brain sections and staining with mucicarmine (spe-
cific for cryptococci) or H&E. Histological analysis of brain slices from brains
of mice inoculated with the H99 (A, C, E, and G) revealed lesions filled with
cryptococci at various stages of cell division (arrows point to cryptococci
within lesions), consistent with fungal disease of the CNS (n 12). However,
brain sections from mice infected with the mpr1mutant strain (B, D, F, and
H) at 48 h p.i. (A and D), 24 h p.i. (F), or 12 h p.i. (H) revealed a complete
absence of cryptococcus-filled lesions, indicating no brain pathology (n 12).
Brain sections were stained with mucicarmine (A, B, E, F, G, and H) or H&E (C
and D).
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Adhesion/cell association assay of C. neoformans with hCMEC/D3
cells.hCMEC/D3 cells were grown to confluence on collagen-coated tran-
swells as discussed above. An inoculum of 1 106 C. neoformans cells in a
50-l phosphate-buffered saline (PBS) volume was added to the endothe-
lial barrier at the start of the experiment. After the indicated amount of
incubation time, the endothelial barrier was washed 3 times with 1 PBS
and either lysed with water to determine the number of yeast cells that
adhere to and associate with the barrier or incubated overnight to assess
the number of yeast cells that transmigrate across the barrier after the
initial adhesion step. This last transcytosis step was done to show that a
transcytosis defect follows an initial adhesion defect.
ExpressionofCnMPR1 cDNA inSaccharomyces cerevisiae andmea-
surement of proteolytic activity of Mpr1. The CnMPR1 cDNA contain-
ing a C-terminal 6-HIS tag was cloned into the EcoRI and HindIII sites
of an episomal yeast expression vector under the constitutive GDP pro-
moter with the following primers: forward, GTAGAATTCATGCGCTCC
TCCGCGCTCATC; and reverse, TACAAGCTTTCAAGATTTGGTCGG
CCTGAA. The plasmid was transformed into a wild-type strain (W303) of
Saccharomyces cerevisiae via electroporation (it should be noted that S.
cerevisiae does not express any homologues of the M36 fungalysin class of
metalloproteases, including MPR1). Expression was confirmed by reverse
transcriptase PCR. Large quantities of CnMpr1 was extracted from
500-ml cultures of S. cerevisiae expressing CnMPR1. Yeast cells were
grown overnight at 30°C in yeast nitrogen base (YNB) medium lacking
uracil. Cultures were centrifuged for 5 min at 5,251 g in 250-ml Falcon
tubes to pellet yeast. Pellets were resuspended in 4 ml morpholineethane-
sulfonic acid (MES)-buffered saline (pH 6.8, containing 1% Nonidet
P-40, 300 mM NaCl, 20 mM imidazole, and 120 l yeast protease inhib-
itor cocktail [Sigma-Aldrich, St. Louis MO]) with the addition of acid-
washed glass beads (0.5 mm; Sigma-Aldrich). The yeast-bead mixture was
vortexed and iced in altering 1-min cycles at 4°C Lysates were separated
from the beads by centrifugation at 5,251  g for 5 min at 4°C and then
centrifuged again to remove debris. The protein Mpr1 was isolated from
the crude lysate by passage through gravity-flow 1.5-ml nickel-
nitrilotriacetic acid (Ni-NTA) columns (Qiagen, Valencia, CA) according
to the directions of the kit (note that buffer composition was changed
from using 50 mM phosphate buffer at pH 7.2 to using 50 mM MES buffer
at pH 6.8) and eluted into a 10-ml volume. Eluate was concentrated by
centrifugation on 30,000-molecular-weight-cutoff (MWCO) Amicon Ul-
tra centrifuge columns (Millipore, Billerica, MA) for 15 min at 4°C at
5,251  g. Concentrates were washed twice with MES-buffered saline,
pH 6.8 (50 mM MES and 150 mM NaCl). Final protein concentrations
were determined by a Bradford assay (Bio-Rad). The protein activity assay
was performed by serially diluting Mpr1 in 2-fold dilutions, ranging from
100 g/ml to 0.78 g/ml. The activity was assayed using a Pierce fluores-
cent protease activity assay kit (Thermo Scientific), according to manu-
facturer’s directions. Fluorescence polarization (Excitation, 488 nm;
emission, 535 nm) was measured every 5 min at 30°C on a SpectraMax M5
microtiter plate reader (Molecular Devices, Sunnyvale, CA) and analyzed
using the Excel 2011 software program (Microsoft, Redmond, WA).
SEM. hCMEC/D3 cells were grown on transwell filters (8 m; BD
Biosciences) under the same conditions used for the transcytosis assays.
Approximately 2 106 cells of a wild-type strain of C. neoformans (H99)
were added to the top chamber for 1 h. The transwell filters were then
washed with 1 PBS to remove nonspecific adhering yeast cells, fixed in
Karnovsky’s fixative, and sent to an on-campus scanning electron micros-
copy (SEM) facility for sample processing (Electron Microscopy Lab,
University of California, Davis [UC Davis]). For SEM preparation of
C. neoformans in the absence of an endothelial barrier, the fungal cells
were grown overnight in yeast extract-peptone-dextrose (YPD), washed
in PBS, spun down, and fixed in Karnovsky’s fixative.
Macrophage intracellular survival assay. J774A.1 (ATCC TIB-67,
kindly provided by R. Tsolis, UC Davis) is a macrophage-like cell line
from a BALB/c, haplotype H-2d, reticulum sarcoma used in the assay.
Macrophages were grown at 37°C with 5% CO2 in Dulbecco’s modified
Eagle medium (DMEM) (11995; Gibco) supplemented with 10% heat-
inactivated fetal bovine serum (16140-071; Invitrogen), 1% nonessential
amino acids (21340; Gibco), 50 g/ml penicillin-streptomycin (Pen/
Strep) (15070-063; Gibco), and 10% NCTC-109 medium (11140; Gibco).
J774A.1 was grown in 25-cm2 or 75-cm2 flasks (136196 or 156499;
Thermo Sci Nunc) and used between passages 4 and 15.
For the assay, 2.5  105 J774A.1 cells were counted using a hemacy-
tometer (1475; Hausser Scientific) and grown in 96-well culture plates
(353072; BD Falcon) overnight. C. neoformans was cultured overnight in
YPD plus 2% glucose at 30°C with agitation. Cultures were then synchro-
nized and normalized based on the absorbance value measured (optical
density at 600 nm [OD600]) and allowed to grow overnight. Using a he-
macytometer, 1  106 C. neoformans cells were added to macrophages
supplemented with 100 U/ml mouse gamma interferon (IFN)
(RM200120; Thermo Sci Pierce Protein Research products), 0.3 g/ml
lipopolysaccharide (LPS) (L4391; Sigma), and 1 g/ml mAb18B7 (kindly
provided by A. Casadevall, Yeshiva University). To obtain a CFU count
for C. neoformans following incubation with macrophages, J774A.1 cells
were lysed using 100 l of ice-cold 0.05% SDS. Lysed J774A.1 cells were
then serially diluted and plated on YPD plus Pen/Strep plates for 48 h at
30°C for CFU determination
Two experiments were done in parallel: experiment 1, to assess the
association of thempr1 strain versus that ofC. neoformansH99 cells after
an initial 1-h incubation with the macrophage cell line J774A1, and ex-
periment 2, to assess the intracellular survival of the mpr1 strain versus
that of H99 cells in macrophages 23 h following the 1-h initial incubation
period. In experiment 2, nonadherent cryptococcal cells were washed
away at 1 h (3 times with 1 PBS), and the infected macrophage culture
was replenished with fresh medium (DMEM plus supplement) and al-
lowed to continue for another 23 h. Therefore, the CFU obtained from
experiment 1 represented the yeast “inoculum” used in experiment 2. The
advantage of this experimental design was that the “inoculum” as defined
represented only the number of yeast cells that adhered to or was inter-
nalized by macrophages at 1 h of infection. This reduces any variations
due to growth differences between mpr1 cells and H99 cells in DMEM.
Inhalationmodel (survival study andCFUanalysis). (i) Experimen-
tal parameters. Yeast cells (1  107) in a 50-ml volume were used to
inoculate mice. Mice (A/J strain, 000646; Jackson Laboratories) were 5
weeks old, inbred, and housed with 3 to 4 animals per cage (n 7 animals
per group: wild type [WT], reconstituted, and mutant).
(ii) Preparation of yeast inoculum.Frozen stocks of the 3 yeast strains
used in the study (H99, thempr1 strain, and Rec1) were streaked on YPD
plates and incubated overnight at 30°C. Colonies were then grown in
liquid YPD overnight at 30°C until log phase (approximately 16 h). Cul-
tures were regrown a second time (to log phase) by adding 100l of liquid
culture into fresh YPD to ensure that yeast colonies were robust. Ten
milliliters of each cultured strain was cleaned with sterile 1 PBS
(4,000 rpm, 4 min, at 25°C) and resuspended in YPD. The concentration
of the original culture was determined by hemacytometer count (Brite-
Line) and was diluted in 1 sterile PBS to a final concentration of 2 
108 cells/ml (equates to 1 107 cells/50-l volume).
(iii) Inoculation (survival assay). After arrival at our animal facilities,
the 4-week-old mice were given 1 week to acclimate and given food and
water ad libitum. Experiments were conducted in a separate surgical
room. Mice were placed under 5% isoflurane anesthesia (2.5% mainte-
nance dose) and inoculated with 1  107 cells in 50-l volume through
the nares. The animals were suspended by their top incisors in order to
extend their neck, thus ensuring that the inoculum was inhaled smoothly
with minimal obstruction. After applying the inoculum, mice were sus-
pended for another 30 s to ensure that all of the inoculum was inhaled.
Changes in the health status of the animals were monitored, and body
weight was recorded daily until they showed signs of sickness due to the
infection. Animals were sacrificed when a loss of 15% of peak body weight
was observed or when a loss of 1 g of body weight was observed for 3
consecutive days. Other signs of sickness were monitored, including leth-
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argy and lack of activity and grooming (indicated by ruffled fur). Mice
were sacrificed by an overdose of pentobarbital (Fatal Plus; MWI Veteri-
nary Supply) at 150 mg/kg body weight. Survival data were collected and
analyzed using the GraphPad-Prism 5.0 software program.
(iv) Tissue homogenization (CFU analysis). Lungs and brains (and
other organs) were collected for homogenization immediately after the
animals were sacrificed. Lungs were cut into several pieces, mashed dry
with a mortar and pestle for 1 min, and suspended in 5 ml of 1 PBS.
Brains were mashed dry for 30 s and suspended in 1 PBS. Original
homogenized tissue was considered 1. Lung tissue was serially diluted
with 1 PBS to 100, 1,000, and 10,000 dilutions; brain tissue was
diluted to 10, 100, and 1,000 dilutions; heart, spleen, and kidney
were diluted to 10 and 100. One hundred microliters of each respec-
tive dilution was spread on YPD plates containing penicillin-
streptomycin and incubated for 2 days at 30°C. Total CFUs were calcu-
lated based on the number of colonies counted on the plate, plating
volume (100l), dilution (from 1 to 10,000), and the original volume
of the homogenized tissue (5 ml). With a few exceptions, we tried to count
plates with at least 100 colonies to maximize accuracy.
Intravenous model (survival study and CFU analysis). (i) Experi-
mental parameters. Yeast cells, 1.2 106 in a 200-l volume, were used
to inoculate mice. Mice (A/J strain, 000646; Jackson Laboratories) were 8
weeks old, inbred, and housed with 3 to 4 animals per cage (n 8 animals
per group: WT, reconstituted, and mutant).
(ii) Preparation of yeast inoculum. The inoculum was prepared as
described above. The concentration of the original culture was diluted in
YPD to a final concentration of 6 106 cells/ml (equates to 1.2 106 cells/
200 l total volume).
(iii) Inoculation (survival assay).Upon arrival at our animal facilities,
7-week-old mice were given 1 week to acclimate and given food and water
ad libitum. Experiments were conducted in a separate surgical room. A/J
mice, under 3% isoflurane anesthesia (1% maintenance dose as needed),
were inoculated with 1.2 106 cells in a 200-l total volume through the
lateral tail vein. Mice were held briefly in a restrainer (Kent Scientific)
during anesthesia and injection. Once the tail vein became dilated by
exposure to a heat lamp, it was disinfected with alcohol swabs (Becton,
Dickinson). Thirty-gauge, 1/2-in. needles (Becton, Dickinson) and 1-ml
tuberculin syringes (Kendall) were used to deliver the inoculum. After
injection was completed, mice were given fresh oxygen until they awoke.
Mice were monitored as discussed above and sacrificed with an overdose
of pentobarbital (Fatal Plus; MWI Veterinary Supply) at 150 mg/kg body
weight.
(iv) CFU analysis. Brains were collected for homogenization immedi-
ately after the animals were sacrificed. Brains were mashed on a mortar
and pestle, dry, for 30 s and resuspended in 5 ml of 1 PBS. Original
homogenized tissue was considered 1. Brain tissue was serially diluted
with 1 PBS to 10, 100, and 1,000 dilutions (1 ml of homogenate in
9 ml 1 PBS). Ten milliliters of each respective dilution was spread on
YPD containing penicillin-streptomycin and incubated for 2 days at 30°C.
Total CFU were calculated based on the number of colonies counted on
the plate, plating volume (100l), dilution (from 1 to 1,000), and the
original volume of the homogenized tissue (5 ml).
Intravenous model: brain burden time course (CFU analysis and
histology). (i) Experimental parameters.Yeast cells (5 105) in a 200-l
volume were used to inoculate mice. Mice (A/J strain, 000646; Jackson
Laboratories) were 8 weeks old, inbred, and housed with 3 to 4 animals per
cage. The number of animals used per groups (WT and mutant) was 4 per
time point (12 h, 48 h, and 72 h). Three of the animals per group were used
for CFU analysis, and one was saved for histological analysis.
(ii) Preparation of yeast inoculum. The inoculum was prepared as
described above. The concentration of the original culture was diluted in
1 sterile PBS to a final concentration of 2.5 106 cells/ml (equates to 5
 105 cells/200 ml total volume).
(iii) Inoculation (CFU analysis). Injection protocols were the same as
discussed above. Mice were sacrificed at 12 h, 24 h, and 72 h using Pento-
barbital (150 mg/kg of body weight). Brains, extracted immediately fol-
lowing euthanasia, were mashed dry for 30 s and suspended in 3 ml YPD
(designated 1). The homogenate was serially diluted to 10 and 100
(200 l of homogenate diluted in 1,800 l YPD). Two hundred microli-
ters of each respective dilution was spread on YPD plates containing P/S
and incubated for 2 days at 30°C. Total CFUs were calculated based on the
number of colonies counted on the plate, plating volume (200 l), dilu-
tion (from 1 to 100), and the original volume of the homogenized
tissue (3 ml).
(iv) Histology. Brains were fixed in 4% paraformaldehyde prior to
sectioning. Sectioning was carried out by the UC Davis Pathology Labo-
ratory. Briefly, 20 consecutive, longitudinal sections (50 m apart) were
taken and stained with mucicarmine or H&E (hematoxylin and eosin)
stain.
Intraparenchymal survival study (CFU analysis only). (i) Experi-
mental parameters. Yeast cells (1 104) in a 60-l volume were used to
inoculate mice. Mice (A/J strain, 000646; Jackson Laboratories) were 10
weeks old, inbred, and housed with 3 to 4 animals per cage (n 6 animals
used per group, WT and mutant).
(ii) Preparation of yeast inoculum. Inoculum was prepared as de-
scribed above. The concentration of the original culture was diluted in 1
sterile PBS to a final concentration of 1.67 106 cells/ml (equates to 1
104 cells/60 ml, total volume).
(iii) Inoculation (CFU analysis). Mice were anesthetized using isoflu-
rane anesthesia and randomized for intracranial inoculation of C. neofor-
mans strains H99. Inoculation was delivered as a 60-l volume through a
27-gauge needle fastened to a tuberculin syringe with a cuff to prevent
penetration of more than 1 mm. A midline puncture through the cranial
vault approximately 6 mm posterior to the orbit was made, and the inoc-
ulum was injected, after which the mice were allowed to recover. The
euthanasia protocol was the same as that described above. Mice were
sacrificed at 48 h using pentobarbital (150 mg/kg of body weight). Brains,
extracted as soon as possible following euthanasia, were mashed dry for
30 s and suspended in 3 ml of YPD (considered 1). The homogenate was
serially diluted to 10 and 100 dilutions (200 l of homogenate was
diluted in 1,800 l YPD). Two hundred milliliters of each respective di-
lution was spread on YPD plus Pen/Strep and incubated for 2 days at 30°C.
Total CFUs were calculated based on the number of colonies counted on
the plate, plating volume (200 l), dilution (from 1 to 100), and the
original volume of the homogenized tissue (3 ml).
All experiments involving vertebrates were in agreement with ethical
regulations established by the UC Davis Institutional Animal Care and
Use Committee (IACUC).
Statistical analysis. For the vertebrate studies, sample size was deter-
mined by power analysis (G*Power3.1 software program). Significance of
survival curves for the vertebrate studies was determined by using the
Wilcoxon test (GraphPad-Prism 5 software). The statistical significance of
the data presented in Fig. 1, 2, and 3 was determined by an unpaired t test
with Welch’s correction (unequal variance) or by one-way analysis of
variance (ANOVA) (GraphPad-Prism 5).
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